Ryde

Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ERX-315 in patients with advanced solid tumors. This study focuses on individuals whose tumors have not responded to approved systemic therapies. The trial includes various types of metastatic cancers such as breast, ovarian, endometrial, liver, and pancreatic cancers. Participants will receive the investigational drug ERX-315 through intravenous injections twice a week, starting at a dose of 0.4 mg/kg. The treatment is given in 21-day cycles, with dose escalation to determine the maximum tolerated dose and recommended phase 2 dose. This open-label study includes both dose escalation and cohort expansion phases. During the study, researchers will monitor participants for dose-limiting toxicities, adverse events, and laboratory abnormalities over periods of up to 84 days. They will assess safety and tolerability, as well as pharmacokinetic data. Patients will be evaluated regularly for measurable disease response, organ and blood function, and overall health status, with follow-up lasting at least three months to determine treatment effects and safety outcomes.

Researchers are evaluating the safety, tolerability, and preliminary anti-tumor activity of LM-168 alone or combined with toripalimab in adults with advanced solid tumors. The study includes phase I to find the recommended dose and maximum tolerated dose, and phase II to assess early signs of tumor response. Participants must have advanced solid tumors that have progressed or for which no standard therapy is available. The treatments studied are LM-168 and toripalimab, both given intravenously every three weeks. The study includes a dose escalation phase to determine safe dosing and a dose expansion phase to further assess effectiveness. Participants may receive LM-168 alone or in combination with toripalimab depending on the study stage. Participants will be monitored for safety and treatment effects for up to 78 weeks, including checking for side effects, vital signs, laboratory tests, heart function, and tumor response. The main outcomes measured are adverse events, dose-limiting toxicities, serious adverse events, and objective tumor response rates. The study collects detailed health data such as blood tests, ECGs, echocardiography, and performance status scores throughout the study period.